Author: eradmin

Posted on

Delayed Elections Are Underway in Ethiopia

Delayed elections are underway Thursday in four regions of Ethiopia.

Voters in three regions will decide who wins dozens of parliamentary seats in the last round of voting before Prime Minister Abiy Ahmed forms a new government on Oct. 4.

Voters in the fourth region will decide whether to establish their own regional state.

The parliamentary elections are being held in the Somali region, the eastern city of Harar, and in the southwestern Southern Nations, Nationalities, and Peoples’ Region (SNNPR).

Voters in SNNPR are also deciding whether or not to form a regional state.

The elections were delayed by a variety of voter registration irregularities, legal disputes, and security issues.

Abiy is facing mounting global pressure over the war in the northern region of Tigray. Conflict erupted in November 2020 between federal and allied regional forces and forces backed by the Tigrayan People’s Liberation Front.

Ethiopia’s parliament consists of 547 seats, 47 of which are being contested. Abiy’s party previously won 410 of the 436 parliamentary seats that were contested in the June election. It is uncertain when elections for the remaining seats, some of which are in Tigray, will take place.

The TPLF regained control of Tigray in June after months of fighting. The United Nations has said parts of Tigray are experiencing famine because of the war.

Source: Voice of America

Posted on

Former Malawi Lawmaker Commits Suicide at Parliament

A former high-ranking lawmaker in Malawi committed suicide Thursday afternoon in the country’s parliament building.

Clement Chiwaya, 50, a former second deputy speaker, fatally shot himself in the head with a pistol while inside the National Assembly. Details about what led Chiwaya to kill himself remained sketchy.

The parliament said in a statement that the public would be informed at an appropriate time, as the Malawi Police Service was investigating the incident.

When in office, Chiwaya represented the opposition United Democratic Front.

According to the statement from parliament, Chiwaya recently was involved in a court case regarding his vehicle. The car was in an accident before the transfer of ownership was completed, and the insurance had expired.

Chiwaya sought help from the government’s Office of the Ombudsman, who made a determination in his favor, but Malawi’s High Court set the determination aside.

The parliament statement said guards have the proper equipment and protocols to ensure safety in the building. However, Chiwaya’s suicide raised concerns.

Former military officer Sheriff Kaisi, a security expert based in Blantyre, said, “To me, I would say that there is negligence on how security should be provided at high-risk places like parliament. This is a wake-up call in the management of security. There is no way you can manage security in that sense, when you have cameras and detectors.”

Chiwaya had used a wheelchair for a number of years. In its statement, the National Assembly said that while Chiwaya’s entrance had set off alerts when he passed through metal detectors Thursday, the alerts were deemed to be from the wheelchair, and therefore guards did not look for any firearms.

Source: Voice of America

Posted on

WHO: Most of Africa Has Missed 10 Percent COVID-19 Vaccination Goal

Fifteen African countries have succeeded in fully vaccinating at least 10 percent of their populations against COVID-19 by September 30, a goal set by the World Health Organization in May. However, that leaves two-thirds of the continent’s 54 nations extremely vulnerable to the deadly disease.

Several countries have performed extremely well. Seychelles and Mauritius have fully vaccinated more than 60 percent of their populations and Morocco has inoculated 48 percent against the coronavirus.

Richard Mihigo is coordinator of the Vaccine-preventable Diseases Department in the WHO’s regional office for Africa. He said those countries were able to achieve and even excede the 10 percent target because they had a steady vaccine supply available.

He said most had the money to strike bilateral deals to procure vaccine in addition to the supplies delivered through the COVAX facility.

“Unfortunately, 70 percent of African countries have missed this important milestone to protect their most vulnerable, with half of the 52 countries with COVID-19 vaccination programs in Africa having inoculated less than two percent of their populations,” said Mihigo.

That compares to an inoculation rate of 50 percent or higher in wealthier countries.

The WHO reports monthly vaccine deliveries to Africa have increased 10-fold since June. However, it notes more than double that amount is needed to reach the 40 percent immunization target of Africa’s 1.3 billion people by the end of the year.

Mihigo said COVAX is identifying countries that do not have the means to procure vaccines and put them in the front of the line to get enough doses to cover their most at-risk populations. However, he said pledges of doses by wealthier countries need to materialize soon.

“Starting next week, we are sending multi-disciplinary teams of international experts to countries that are struggling to scale up their operations so that we can drill down and identify the bottlenecks so that the local authorities and their partners can remedy them as they continue to rollout the vaccines,” said Mihigo.

On a more positive note, the World Health Organization says COVID-19 infections in Africa dropped by 35 percent to just over 74,000 last week, with more than 1,700 deaths reported in 34 countries.

Despite the declining numbers, the WHO warns people must remain vigilant and continue to adhere to proven public health measures to save lives. Those include the wearing of masks, regular hand washing, and physical distancing.

Source: Voice of America

Posted on

Sinocare présente ses produits pour la gestion du diabète et des maladies chroniques lors de la deuxième exposition économique et commerciale Chine-Afrique

CHANGSHA, Chine, 29 septembre 2021 /PRNewswire/ — Sinocare, le leader mondial du développement de tests médicaux, a présenté sa dernière gamme de produits lors de la deuxième exposition économique et commerciale Chine-Afrique (CAETE), qui s’est tenue du 26 au 29 septembre au centre international de congrès et d’expositions de Changsha. Sinocare a présenté, sur le stand qui lui était réservé, différents types de produits pour la gestion des maladies chroniques, notamment le glucomètre, le tensiomètre, le détecteur de lipides sanguins et le détecteur d’acide urique, et a également dévoilé son analyseur multifonction portable analyseur HbA1C portable et son détecteur par fluorescence de produits finis de glycation avancée.

Sinocare Headquarters

CAETE est une plate-forme importante pour la Chine et les pays africains pour mener une coopération économique et commerciale, et des échanges et dialogues intéressants. Sous le thème « Nouveau départ, nouvelles opportunités, nouvelles réalisations », l’événement de cette année est axé sur les domaines des produits alimentaires et agricoles, des industries médicales et de santé, de la coopération en matière d’infrastructures et de chaînes industrielles, ainsi que de la coopération économique et commerciale approfondie. Sinocare a présenté un certain nombre de produits de pointe qui favoriseront davantage la coopération entre les secteurs médical et de la santé de la Chine et de l’Afrique, et permettront la construction d’une communauté médicale commune.

« Chez Sinocare, notre vision consiste à fournir des produits et des services de haute qualité aux personnes souffrant de diabète et d’autres maladies chroniques afin de les aider à améliorer leur qualité de vie. Nous avons hâte de travailler avec des professionnels de santé et des entreprises privées en Afrique pour fournir à davantage de personnes des solutions accessibles et abordables pour la gestion du diabète », a déclaré Louis Hu, directeur régional de Sinocare pour l’Afrique.

Lors de la CAETE, Sinocare a lancé ses produits phares pour quatre maladies chroniques : le Gold AQ PLUS et le Safe AQ Smart pour la glycémie, l’AES-U111 pour la pression artérielle ; iCARE2100 pour l’analyse multi-index ; et PCH50 pour l’analyse de l’HbA1C. Avec des caractéristiques et des avantages notables, les produits de Sinocare ont attiré l’attention d’innombrables participants qui se sont arrêtés sur le stand pour une consultation.

Gold AQ PLUS possède des propriétés électrochimiques supérieures et une résistance à la corrosion extrêmement importante avec une bandelette de test d’électrode en or pur à 99,99%. Le système est capable de détecter avec précision la température de l’échantillon de sang, le HCT et la température ambiante, et de corriger automatiquement les écarts de résultat. Son autre glucomètre phare exposé était le Safe AQ Smart, doté d’un système FAD-GDH pour des résultats exacts et précis, d’un système d’exploitation facile d’utilisation qui ne nécessite aucun codage et d’une éjection automatique des bandelettes de test.

Pour les patients présentant un taux de cholestérol élevé, le détecteur de lipides et de glycémie à double usage peut être utilisé pour la mesure quantitative du CT, du HDL, des TG et du GLU. Le détecteur a un débit rapide de glucose en 5s et de lipides en 100s, et prend en charge l’impression en ligne par USB et la transmission de données par Bluetooth. Par ailleurs, le système de surveillance de la glycémie et de l’acide urique à double fonction Safe AQ-UG peut être utilisé pour les personnes souffrant de diabète et d’hyperuricémie. Safe AQ UG respecte la norme ISO15197 2013 et est équipé d’une éjection automatique des bandelettes et d’un code intelligent pour les tests d’acide urique.

En outre, iCARE2100 est l’instrument multiplateforme innovant de Sinocare possédant plusieurs indicateurs pour réaliser des tests pratiques au chevet du patient. Alimenté par la technologie principale Liquid Phase iPOCT, iCARE 2100 prend en charge une haute précision et une détection instantanée. Sans utiliser d’autres consommables, les praticiens peuvent réduire les coûts des tests sans compromettre la qualité.

Au-delà de la Chine, Sinocare est présent dans 42 pays d’Afrique, dont l’Algérie, l’Égypte, l’Éthiopie, l’Afrique du Sud et plus encore. L’ensemble de ses ventes à travers le continent ont atteint plus de 110 millions de yuans, les produits les plus populaires de Sinocare étant les systèmes de surveillance de la glycémie, les tensiomètres, les analyseurs de profil lipidique et les détecteurs de HbA1c. La croissance rapide de Sinocare en Afrique s’explique par ses systèmes indolores et faciles à utiliser qui conviennent à un grand nombre de personnes, ainsi que sa stabilité de prélèvement d’échantillons et de bandelette de test avec une technologie brevetée.

Sinocare continue de se développer activement en Afrique et prévoit de créer des usines de production en Algérie et en Égypte pour réaliser la production locale de bandelettes de test de glycémie. Cette initiative réduira considérablement les coûts et le temps de transport, et accélérera ses capacités à fournir aux populations africaines des produits pour la surveillance du diabète.

À propos de Sinocare : 

Sinocare compte 19 ans d’expérience dans le secteur des lecteurs de glycémie depuis sa fondation en 2002. La société se consacre au développement, à la production et à la vente de la détection rapide des maladies chroniques grâce à l’utilisation de la technologie des biocapteurs. En 2016, après avoir acquis avec succès Nipro diagnostic Inc. (maintenant renommée Trividia Health Inc.) et PTS Diagnostics Inc., Sinocare est devenu le numéro 5 mondial des fabricants de glucomètres et l’une des principales sociétés au monde d’appareils de test au point de service.

Pour plus d’informations, veuillez consulter le site : www.sinocareintl.com

Facebook : Sinocare In’tl 

Contact pour les médias : Echo Gao
Intl_mkt@sinocare.com

Photo – https://mma.prnewswire.com/media/1637313/Sinocare_Headquarters.jpg

 

Posted on

Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19

ADG20 Continues to be Well Tolerated in Healthy Volunteers with Prolonged Half-Life and Serum Virus Neutralization Activity Observed out to Six Months in Ongoing Phase 1 Study

Data from Quantitative Systems Pharmacology/Whole-Body Physiologically Based Pharmacokinetic Modeling Support Evaluation of 300 mg Intramuscular Dose of ADG20 Given as a Single Intramuscular Injection in Ongoing Phase 2/3 Studies

Data to be Presented During IDWeek 2021 and 19th Annual Discovery on Target Conference

WALTHAM, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced new data from the company’s COVID-19 antibody program. Updated, six-month data from its ongoing Phase 1 study of ADG20 in healthy participants and data validating the selection of the 300 mg intramuscular (IM) dose given as a single injection that is being evaluated in the company’s ongoing global Phase 2/3 treatment (STAMP) and prevention (EVADE) clinical trials will be presented during four poster sessions at the Infectious Disease Society of America’s IDWeek 2021, being held from Sept. 29 – Oct. 3, 2021. In addition, Adagio’s chief scientific officer, Laura Walker, Ph.D., will present a subset of the ADG20 Phase 1 data as well as background on the identification and optimization of this differentiated antibody clinical candidate in an oral presentation at the 19th Annual Discovery on Target Conference on Sept. 30, 2021.

“The continued strength of the safety and pharmacokinetic data from our Phase 1 study is encouraging and further underscores the potential impact an antibody like ADG20 – which was designed to be potent, broadly neutralizing and delivered as a single IM injection – could have on people with or at risk of COVID-19,” said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. “These Phase 1 data combined with our dose selection strategy, which relied on our innovative modeling approach, have allowed us to initiate and advance our pivotal trials of ADG20 in the treatment and prevention of COVID-19. We anticipate these data will support an Emergency Use Authorization (EUA) application in the first quarter of 2022, which could enable us to bring an important treatment option to patients.”

Phase 1 Trial Update
Adagio is evaluating ADG20 in a Phase 1 randomized, double-blind, placebo-controlled single ascending-dose study to assess safety and tolerability, pharmacokinetics (PK), immunogenicity, and serum virus neutralizing activity of ADG20 ex vivo against SARS-CoV-2. Data from a six-month evaluation timepoint confirmed the extended half-life of ADG20, which approached 100 days based on data from the 300 mg IM dose that was given as a single injection. In addition, 50% serum virus neutralization titers at six months after a 300 mg IM dose of ADG20 were similar to observed peak titers with the mRNA-1273 vaccine and exceeded those achieved with the AZD1222 vaccine series. Importantly, ADG20 was well tolerated with no study drug-related adverse events (AEs), serious AEs, or injection-site or hypersensitivity reactions reported through a minimum of three months follow-up across all cohorts. Participants will continue to be followed through 12 months to assess safety and tolerability, PK, immunogenicity and serum virus neutralizing activity.

Phase 1 Poster Information: (633) Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)

Dose Selection Strategy
To support dose selection for Adagio’s global Phase 2/3 STAMP and EVADE clinical trials, the company modified an existing quantitative systems pharmacology whole-body physiologically-based pharmacokinetic (QSP/PBPK) model to better characterize the PK of extended half-life monoclonal antibodies in serum and key sites of viral replication in the respiratory tract. Adagio’s model adequately a priori predicted the observed ADG20 serum PK in non-human primates (NHPs) and humans. The model was further optimized based on data from Adagio’s Phase 1 clinical trial and then applied for dose selection for STAMP and EVADE.

For the STAMP treatment trial, data compiled to date suggest that the 300 mg IM regimen has a projected ability to rapidly achieve and maintain target concentrations at key tissue sites of viral replication, including the ability to attain near complete (> 90%) and durable (> 28-day) SARS-CoV-2 receptor occupancy across a range of baseline viral loads. Further, for the EVADE prevention trial, data compiled to date suggest the 300 mg IM regimen has a projected ability to rapidly exceed target serum concentrations in the majority of simulated patients and to maintain potentially effective concentrations for up to 12 months.

Dose Selection Poster Information

  • (1086) A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model that a priori Predicts Intramuscular (IM) Pharmacokinetics of ADG20: an Extended Half-life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)
  • (1089) Use of a Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Prevention of Coronavirus Disease (COVID-19)
  • (1088) A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment of Coronavirus Disease (COVID-19)

The STAMP and EVADE clinical trials are currently ongoing and enrolling patients globally. For more information, please visit clincialtrials.gov.

About ADG20
ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization against SARS-CoV-2 and additional clade 1 sarbecoviruses, by targeting a highly conserved epitope in the receptor binding domain. ADG20 displays potent neutralizing activity against the original SARS-CoV-2 strain as well as all known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc-mediated innate immune effector activity. ADG20 is administered by a single intramuscular injection, and was engineered to have a long half-life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of our planned EUA application, initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; our ability to obtain and maintain regulatory approvals for, our product candidates; our ability to identify patients with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our manufacturing capabilities and strategy; and our ability to successfully commercialize our product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, those risks described under the heading “Risk Factors” in Adagio’s prospectus filed with the Securities and Exchange Commission (“SEC”) on August 6, 2021 and in Adagio’s future reports to be filed with the SEC, including Adagio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts:
Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

Posted on

Developing China and Benefiting the World

Celebrating the 72nd Anniversary of the Founding of the People’s Republic of China

China will celebrate the 72nd Anniversary of the founding of the People’s Republic on October 1st, 2021.

After 72 years of continuous struggle, China has created two miracles: rapid economic development and long-term social stability. In 1949, China was poor and blank, with a per capita GDP of less than 70 U.S. dollars and an average life expectancy of 35 years. Today, China has become the world’s second largest economy, largest industrial manufacturing country, and largest goods trading country. China’s output of more than 220 industrial products ranks first in the world. The total number of scientific research personnel and patent applications for inventions of China also ranks first in the world. The Communist Party of China (CPC) has led the Chinese people to realize the First Centenary Goal of building a moderately prosperous society in all respects. All the rural population has been lifted out of poverty as defined by the existing standard. The world’s largest social security system has been built. Through the arduous efforts of people of all ethnic groups across the country, China has achieved economic growth and maintained social stability and development while fighting the COVID-19 pandemic.

In the past 72 years, China has always been a builder of world peace, contributor to global development, defender of international order and provider of public goods. China is the largest contributor to peacekeeping operations among the permanent members of the UN Security Council. With contribution of more than 30 percent annually to world growth and as the largest trading partner and largest export market for more than 130 countries and regions in the world, China has become the main anchor and powerhouse in the world economy. Taking active steps to combat global climate change, China has fulfilled its international commitment to reduce carbon emissions by 2020 ahead of schedule. In addition, it has pledged to peak carbon emissions before 2030 and achieve carbon neutrality by 2060. China has also announced it would step up support for other developing countries in developing green and low-carbon energy, and would not build new coal-fired power projects abroad. China is also making outstanding contributions to world public health security. Since the outbreak of the COVID-19 Pandemic, China has been providing timely assistance to the international community. By now, it has provided medical supplies to 150 countries and 13 international organizations, dispatched 37 medical expert teams to 34 countries, provided close to 1.2 billion doses of finished and bulk vaccines to over 100 countries and international organizations, and will step up efforts to provide a total of two billion doses to other countries in the course of this year. In addition to donating 100 million US dollars to COVAX, China will donate 100 million doses of vaccines to other developing countries in the course of this year. At the same time, taking an open and scientific attitude, China will continue to support and engage in global science-based origins tracing, and stands firmly opposed to political maneuvering in whatever form, to the so-called report compiled by the U.S. intelligence community and to U.S. slandering and attacking China on this issue.

The great achievements were achieved by the Chinese people under the leadership of the CPC, which surely will unite and lead the Chinese people to realize the Second Centenary Goal and the great rejuvenation of the Chinese nation. This is because:

First, the CPC always serves the people wholeheartedly. Putting the people first and firmly relying on the people, the CPC has united and lead the people to achieve great achievements one after another.

Second, the CPC works tirelessly to realize its ideals. By insisting on proceeding from reality in everything and leading the people to explore and move forward with unrelenting courage, the CPC has pioneered a path of socialism that is distinctively Chinese, which has refuted the myth that modernization can be achieved only by following the capitalist model.

Third, the CPC is of robust leadership and strong governance ability. Centralized leadership by the CPC serves the best interests of the Chinese people, suits China’s national conditions, and conforms to Chinese history and traditional culture. The CPC has won widespread support from the people.

Fourth, the CPC has always maintained its vigor and vitality by self-reform, self-purification and self-innovation. The CPC takes resolute measures against all phenomena that may undermine its integrity and progressive nature, exercises effective self-supervision, practices strict self-discipline in every respect, strengthens checks and scrutiny over the exercise of power. The CPC has allowed no safe haven, left no ground unturned, and shown no tolerance in fighting corruption, preventing or punishing any action that creates barriers between the Party and the people or infringes on their interests.

Fifth, the CPC contributes to world peace and development. The CPC is a political party that seeks happiness for the people and progress for humanity. Taking a clear-cut stance against hegemony and power politics, it adheres to the path of peaceful development, firmly upholds the international system with the United Nations at the core, promotes democracy in international relations, presses for a new model of international relations based on mutual respect, fairness, justice and win-win cooperation, and promotes the building of a global community of shared future. At the General Debate of the 76th Session of the United Nations General Assembly, President Xi Jinping noted that, right now, COVID-19 is still raging in the world, and profound changes are taking place in human society. The world has entered a period of new turbulence and transformation. It falls on each and every responsible statesman to answer the questions of our times and make a historical choice with confidence, courage and a sense of mission. He also stressed that mankind must beat COVID-19 and win this decisive fight crucial to the future of humanity, must revitalize the economy and pursue more robust, greener and more balanced global development, must strengthen solidarity and promote mutual respect and win-win cooperation in conducting international relations, must improve global governance and practice true multilateralism.

China and Eritrea enjoy profound traditional friendship. Our two countries have always respected and treated each other equally, supported each other on issues concerning each other’s core interests and major concerns, and jointly safeguarded the common interests of our two countries and international fairness and justice. China cherishes the traditional friendship with Eritrea, admires the development progress achieved by the Eritrean people, understands Eritrea’s difficulties, respects Eritrea’s policy of independence and self-reliance, supports Eritrea’s efforts to safeguard national sovereignty and efforts made for social and economic development, and opposes sanctions or threat of sanctions against Eritrea. China is willing to continuously deepen and expand bilateral friendly cooperation in various fields for the benefit of our two peoples. Chinese and Eritrean peoples were, are and will always be good friends, partners and brothers helping and supporting each other.

Source: Ministry of Information Eritrea

Posted on

Training on information technology

The Central Region in cooperation with the department of Statistics and Cartographic System organized training to 60 of its members including 34 females on basic information technology.

Speaking at concluding event of the training, Mr. Tedros Tekle, head of the department of Statistics and Cartographic System, said that the objective of the training that included computer technology, computer network security and computer maintenance was to upgrade the capacity of the staff members and address minor problems that could occur due to system failure.

The representative of the trainees said that the training they received will have significant contribution in facilitating their daily activities.

Mr. Fesehaye Haile, Governor of the Central Region, on his part called on the trainees to upgrade their knowledge practically on the ground and play due part in the effort to provide timely and efficient administrative service,

Source: Ministry of Information Eritrea